Business Context and Reporting Period
This Form 8-K is a Current Report filed by Conduit Pharmaceuticals Inc. (not CDT Equity Inc.) on May 15, 2025. The report details a material corporate action regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate governance event.
Material Changes
- Reverse Stock Split: The Company filed a certificate of amendment to effectuate a 1-for-15 reverse stock split of its outstanding Common Stock.
- Approval: Stockholders approved the split and authorized the Board to determine the ratio at a Special Meeting on May 5, 2025.
- Effective Date: The split becomes effective on May 19, 2025, at 5:00 p.m. Eastern Time.
- Trading Resumption: Common Stock is expected to resume trading on The Nasdaq Global Market on a split-adjusted basis on May 20, 2025, under the existing ticker symbol CDT.
- Fractional Shares: No fractional shares will be issued. Stockholders entitled to fractional shares will receive a cash payment based on the closing price on May 19, 2025.
- CUSIP Update: The post-split CUSIP number will be 20678X 304.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the Reverse Stock Split and its potential impacts. The Company disclaims any obligation to update these statements. No specific financial guidance, management commentary on operations, or new risk factors beyond standard litigation reform act disclaimers are provided in this text.
Investor Verification Checklist
- Verify the 1-for-15 split ratio and the May 19, 2025 effective time.
- Confirm the new CUSIP number (20678X 304) for post-split trading.
- Check the treatment of fractional shares (cash in lieu) and the pricing mechanism (closing price on May 19, 2025).
- Review the press release (Exhibit 99.1) for any additional details on the rationale for the split.